Golimumab for Treating Chronic Inflammatory Joint Diseases in the Adult Population: Clinical Efficacy and Tolerability

Abstract

Due to the recent introduction of golimumab into paediatric rheumatology practice, an overview of the clinical studies of this tumour necrosis factor alpha inhibitor, most of which were conducted with adult patients with rheumatic diseases, has been presented. Clinical laboratory effects and tolerability of golimumab in the form of subcutaneous injections have been analysed for rheumatoid arthritis, psoriatic arthritis, and spondylitis. Evaluation of the efficacy and tolerability of golimumab in long-term observational studies (up to 5 years) has been discussed.

Keywords

• ревматоидный артрит
• псориатический артрит
• анкилозирующий спондилит
• нерентгенографический спондилит
• голимумаб
• эффективность
• переносимость
• педиатрическая ревматологическая практика